The numbers are indeed worse than you think. While Medicare Part D premiums for standalone plans dropped by $3.81 per month in 2026 to $34.50, this modest decrease masks a more troubling reality: out-of-pocket costs climbed to $2,100 annually, the maximum deductible increased to $615, and the true burden falls heaviest on people who take multiple medications or have modest incomes. For beneficiaries managing chronic conditions—and two-thirds of Medicare recipients do—the savings from lower premiums evaporate quickly under the weight of higher deductibles and out-of-pocket caps. Consider this real example: a 68-year-old retiree taking five medications for heart disease, diabetes, and hypertension will typically encounter her $615 deductible by March, then face 25% coinsurance until her out-of-pocket costs hit $2,100—a threshold she might not reach until late fall.
The result is that her net out-of-pocket drug spending for 2026 could easily exceed $2,800 when the deductible, coinsurance, and other cost-sharing are calculated, even as headline figures tout premium reductions. The cruel irony is timing. Income-related surcharges now affect about 8% of Part D beneficiaries earning over $109,000 (single) or $218,000 (married), with surcharges as high as $91 monthly. Meanwhile, half of all Medicare beneficiaries live on $43,200 or less per year—a figure that swallows any premium savings in the face of rising deductibles and out-of-pocket caps.
Table of Contents
- What’s Really Happening With Medicare Part D Costs in 2026?
- Income-Related Surcharges Are a Hidden Tax on Middle-Class Retirees
- The Ten Negotiated Drugs Are Good News, But They’re Probably Not Your Medications
- What Does This Mean for Your Actual Out-of-Pocket Spending in 2026?
- The No-Donut-Hole Benefit Is Now the Baseline, Not a Breakthrough
- Medication Abandonment and Affordability Gaps Among Beneficiaries
- What’s Next for Medicare Part D Affordability in 2027 and Beyond?
- Conclusion
What’s Really Happening With Medicare Part D Costs in 2026?
The headline story oversimplifies the picture. Yes, standalone Part D plan premiums fell to $34.50 in 2026, and medicare Advantage plans with integrated Part D coverage came in at $11.50—both declines from 2025. But premiums represent only one component of total drug costs, and they’re not the component that determines whether a retiree can afford insulin, statins, or blood pressure medications year-round. The base beneficiary premium itself is $38.99 for 2026, a number that matters because beneficiaries in higher-income brackets will pay additional surcharges on top of it. What changed more ominously is the deductible structure. The maximum deductible increased to $615 in 2026, up from $590 in 2025.
For a retiree on a fixed income, this $25 increase means medications won’t be covered until after she’s paid $615 out of pocket. For someone taking a common combination of chronic disease medications, the deductible is often satisfied by March or April. The real financial pressure begins after the deductible, when coinsurance applies—typically 25% of drug costs in the initial coverage phase—until the out-of-pocket spending cap is reached. The out-of-pocket cap itself rose to $2,100 in 2026, up $100 from 2025. This is the total amount a beneficiary must pay before the plan covers 100% of covered drugs for the remainder of that year. For those with expensive medications or multiple prescriptions, this cap will be hit. The Center on Budget and Policy Priorities has noted that average Part D enrollees take four to five prescriptions per month, meaning the cumulative drug costs that push someone toward the $2,100 cap accumulate rapidly.
Income-Related Surcharges Are a Hidden Tax on Middle-Class Retirees
Medicare’s income-related monthly adjusted amount (IRMAA) is the least understood and most resented piece of Part D pricing. For 2026, using 2024 tax return income as the basis, beneficiaries exceed IRMAA thresholds at relatively modest income levels: $109,000 for singles and $218,000 for married couples filing jointly. Once you cross these thresholds, surcharges are added to the base Part D premium. The Part D surcharge ranges from $14.50 to $91.00 monthly depending on income tier, meaning some beneficiaries pay up to $1,092 extra per year on top of their base premium. The limitation here is especially punitive for couples in early retirement. A couple retiring at 62 or 63 might have pension income, social Security, and perhaps investment or rental income that collectively exceeds the $218,000 threshold, even if their actual spending and needs are modest.
Unlike typical income taxes, IRMAA surcharges have no exceptions for medical expenses or life circumstances. A widow or widower whose spouse died in 2024 but whose combined income from that year still exceeded the threshold will continue paying surcharges in 2026 unless they filed a successful appeal. Currently, about 8% of Part D beneficiaries pay IRMAA, but this proportion is steadily growing as retirees approach thresholds that haven’t moved meaningfully in years. Appealing an IRMAA determination is possible—Medicare allows beneficiaries to request a reconsideration based on significant life-changing events—but the burden falls on the beneficiary to identify, document, and submit the appeal. Many retirees remain unaware they can challenge these surcharges, or they assume the process is too complex to pursue. The result is that a significant minority of retirees pay surcharges they might not owe if they knew how to challenge them.
The Ten Negotiated Drugs Are Good News, But They’re Probably Not Your Medications
In what represents genuine progress, Medicare successfully negotiated prices for ten drugs in the Medicare drug price negotiation program, with these negotiated prices effective in 2026. The ten drugs are Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog/Fiasp. The savings are substantial: Eliquis (apixaban), a commonly prescribed blood thinner, will cost $231 for a 30-day supply instead of $521 in 2023—a 56% reduction. Jardiance, used for type 2 diabetes, dropped to $197 from a list price of $573. These negotiations are expected to help nearly 9 million Part D beneficiaries save an estimated $1.5 billion in out-of-pocket costs, which translates to roughly 50% average savings on these specific drugs.
If you take one of these ten medications, congratulations: your 2026 Part D costs will be measurably lower than they would have been. If your doctor prescribed you Eliquis and you’ve been paying hundreds of dollars per month in copayments or coinsurance, the relief will be real and immediate. But the limitation is critical: the ten drugs represent a tiny fraction of the medications covered under Part D. Thousands of other drugs remain subject to full pricing power by manufacturers. A beneficiary taking insulin—protected by a separate $35 monthly cost cap continuing through 2026—alongside a non-negotiated COPD drug, a non-negotiated arthritis medication, and a statin may benefit from insulin’s price cap but still face rising costs for the other three. The negotiation program is expanding, with additional drugs targeted for negotiation in future years, but for 2026, these ten drugs are the entire scope of Medicare’s drug price negotiation efforts.
What Does This Mean for Your Actual Out-of-Pocket Spending in 2026?
The real test of Medicare Part D affordability is what beneficiaries actually pay out of pocket for medications they need. A concrete scenario helps illustrate: consider a 72-year-old with heart disease taking Eliquis, a statin, a beta blocker, and a diuretic. In 2025, her total annual cost for these medications might have been $4,000 or more in out-of-pocket spending. In 2026, with the Eliquis negotiation bringing that drug down by half and other medications hitting the out-of-pocket cap sooner, her true annual out-of-pocket cost might be $2,400—a meaningful reduction, though still substantial on a $45,000 annual income. Contrast this with a beneficiary taking none of the ten negotiated drugs. She might be prescribed a different blood thinner, a newer diabetes drug not yet negotiated, and several other medications.
With the $615 deductible to satisfy first, then 25% coinsurance until hitting the $2,100 out-of-pocket cap, she could easily spend $2,800 to $3,200 for the year depending on drug prices and the specific plan she selected. The gap between a beneficiary whose medications align with negotiated drugs and one whose don’t can be $500 to $1,000 per year—a significant disparity driven by which drugs manufacturers agreed to negotiate and which they refused. One critical tradeoff: beneficiaries who face high out-of-pocket costs have an incentive to ask their doctors for generic alternatives or for alternative drugs on their plan’s formulary that might cost less. This process, called therapeutic substitution, often works. But it also means accepting a medication that is not the doctor’s first choice. For some conditions, this substitution is medically acceptable. For others, especially when a patient has not responded to generics or when brand-name efficacy is materially different, the forced substitution reduces quality of care.
The No-Donut-Hole Benefit Is Now the Baseline, Not a Breakthrough
One genuinely positive note: the coverage gap, long called the “donut hole,” has been eliminated entirely as of 2025 and continues through 2026. In earlier years, beneficiaries would exhaust their initial coverage, enter a gap where they paid full cost, and then reach catastrophic coverage where the plan paid 95% of costs. Today, that gap no longer exists. Once you meet your deductible, you pay coinsurance; once you hit your out-of-pocket cap, the plan covers 100% of covered drugs. This is a substantial protection, but it’s also a baseline expectation that sometimes masks the deeper problem: the out-of-pocket cap itself has crept upward.
An out-of-pocket cap of $2,100 is still $2,100, and for a retiree living on $3,600 per month in Social Security plus modest pensions, reaching that cap represents a major financial event. The elimination of the donut hole deserves credit, but it should not obscure the fact that out-of-pocket maximums continue climbing while beneficiary incomes remain relatively flat. There’s also a less-discussed limitation: the out-of-pocket cap applies only to covered drugs. If a beneficiary’s plan doesn’t cover a medication that her doctor prescribes, or if the plan requires prior authorization that delays access, the cost of that uncovered or delayed medication doesn’t count toward the out-of-pocket cap. This means a beneficiary might pay full price for an uncovered drug, then later hit the $2,100 cap on covered drugs—spending well above the stated maximum. Beneficiaries must monitor their plan’s formulary closely to understand which drugs are covered and which are not.
Medication Abandonment and Affordability Gaps Among Beneficiaries
The broader context is that over one-third—36%—of Medicare beneficiaries delayed or skipped medication doses or refills in 2023 due to affordability concerns. That survey preceded 2026 and included beneficiaries facing the pre-negotiation drug prices that existed in 2023 and 2024. While the negotiation of ten drugs should reduce this proportion somewhat, the underlying driver remains unchanged: millions of beneficiaries cannot afford to pay for the medications their doctors prescribe. This situation is not primarily a premium problem—it’s a deductible, coinsurance, and out-of-pocket cap problem.
A beneficiary paying $34.50 per month in Part D premiums is still paying her deductible before coverage begins, still paying 25% coinsurance afterward, and still facing the $2,100 out-of-pocket maximum. If her medications include non-negotiated drugs that are expensive, she will likely face difficult choices: skip doses, ask the doctor for cheaper alternatives, delay refills, or reallocate money from groceries and utilities to pay for drugs. For beneficiaries living on $43,200 per year or less—half the Medicare population—these are not trivial tradeoffs. A single $2,100 out-of-pocket drug cost represents nearly 6% of their entire annual income.
What’s Next for Medicare Part D Affordability in 2027 and Beyond?
The momentum toward drug price negotiation is accelerating. CMS has announced plans to expand the Medicare drug price negotiation program, with additional drugs targeted for negotiation in future years. However, the pace remains gradual: ten drugs in 2026 negotiation, with larger tranches planned for subsequent years.
Manufacturers have also challenged several negotiated prices in court, arguing that the negotiation process violates their constitutional rights, adding legal uncertainty to whether these negotiated prices will remain in effect. Looking forward, the fundamental tension remains: premiums have modest downward pressure because they’re subject to demographic trends and actuarial factors, but deductibles and out-of-pocket costs continue to rise. Unless Congress intervenes with broader affordability measures—such as further reducing the out-of-pocket cap or eliminating the deductible for low-income beneficiaries—the trajectory for Part D costs will continue upward for most beneficiaries, even as a narrower group benefits from the expanding drug price negotiations. The $35 insulin cap, continuing through 2026, offers one model of how Congress can target specific populations for relief, but insulin represents only a fraction of the medications beneficiaries need.
Conclusion
Medicare Part D in 2026 presents a misleading picture if judged solely by premium decreases. While standalone plan premiums dropped by $3.81 to $34.50 monthly, the deductible increased, the out-of-pocket cap rose to $2,100, and income-related surcharges continue to tax middle-class retirees. Drug price negotiations for ten medications offer real relief for beneficiaries taking those specific drugs, potentially saving them hundreds of dollars. But for the broader population—those taking non-negotiated medications or navigating the complex interplay of deductibles, coinsurance, and income-based surcharges—2026 remains financially challenging.
The pathway forward requires realistic planning and awareness. Beneficiaries should review their 2026 Part D plan options during annual enrollment, ask their doctors whether any of the ten negotiated drugs might be appropriate alternatives to their current regimen, and appeal any IRMAA surcharges if their circumstances have changed since their 2024 tax return. For those with modest incomes, programs like the Low-Income Subsidy program offer additional assistance—a resource underutilized by many who qualify. The numbers for 2026 are indeed worse than a headline about lower premiums would suggest, but vigilance and informed planning can help mitigate the financial burden.